You are here: Industry Insights > NICE

News List

NICE recommends Sobi’s Kineret for first-line use in Still’s disease pharmatimes
March 31, 2021
The National Institute for Health and Care Excellence (NICE) has recommended Sobi’s Kineret for the first-line treatment of the rare inflammatory disorder Still’s disease.
NICE publishes guideline for Covid-19 management in children and adults pharmaceutical-technology
March 25, 2021
The National Institute for Health and Care Excellence (NICE) in the UK has published a guideline for Covid-19 management in children and adults.
New oral chronic lymphocytic leukaemia treatment made available on NHS europeanpharmaceuticalreview
March 22, 2021
AstraZeneca’s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to patients with chronic lymphocytic leukaemia.
NICE recommends Kyprolis triple combination treatment for multiple myeloma pharmatimes
March 22, 2021
The National Institute for Health and Care Excellence (NICE) has recommended a triple combination therapy comprised of Amgen’s Kyprolis, lenalidomide and dexamethasone for the treatment of previously-treated multiple myeloma patients.
NICE approves Lynparza plus Avastin via Cancer Drugs Fund pharmatimes
March 19, 2021
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca/MSD’s Lynparza combined with Roche’s Avastin for certain patients with ovarian cancer via the Cancer Drugs Fund (CDF).
NICE backs AstraZeneca’s Calquence for CLL pharmatimes
March 18, 2021
The UK National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s Calquence for use on the NHS to treat a common form of leukaemia.
NICE rejects AZ’s Lynparza for metastatic prostate cancer pharmatimes
March 10, 2021
The UK’s National Institute for Health and Care Excellence’s (NICE) appraisal committee has chosen not to recommend AstraZeneca’s (AZ) PARP inhibitor Lynparza for BRCA-positive metastatic prostate cancer.
NICE rejects Kyowa Kirin’s rare blood cancer drug Poteligeo for NHS use pharmaceutical-technology
March 05, 2021
The UK’s drug pricing regulator the National Institute for Health and Care Excellence (NICE) has decided not to recommend Kyowa Kirin’s Poteligeo (mogamulizumab) for routine use in the National Health Service (NHS) in England and Wales.
NICE backs selective internal radiation therapy for advanced liver cancer pharmatimes
March 03, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended selective internal radiation therapy (SIRT) for the treatment of advanced liver cancer in final draft guidance.
NICE recommends routine funding for Novartis’ Kisqali pharmatimes
March 01, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended routine access to Novartis’ Kisqali in certain advanced breast cancer patients.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page